News & Events
January 9, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Adrian Adams…
READ MORE
November 20, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that a narrative review of…
READ MORE
SEATTLE, October 17, 2019 — Impel NeuroPharma today announced that Diane Wilfong has been appointed to the Company’s board of directors. Diane brings 30 years of financial and operations experience in large, multinational companies, including most currently serving as Senior…
READ MORE
